A labelling quality issue with the company's manufacturer in China meant it did not receive sufficient monitors to meet an order for myLotus fertility metres by the ShanDong WeiHai HaiChen Pharmaceutical Co.
READ: Concepta says myLotus fertility product got an “excellent reception” at meeting of potential distributors in China
The £600,000 Chinese order will now be delivered in January, meaning revenues from the deal will be recognised in the first quarter of 2018 instead of by the end of 2017 as announced in November.
However, chief executive Erik Henau said the company has had a team on the ground over recent months to tackle the issues in its supply chain as it ramps up production.
“The China team will have the support of David Darrock as chief operating officer who has experience in the move from assembling products in a laboratory environment to full scale commercial manufacturing,” he said.
“We enforce strict quality control standards on our products and as such we have commenced a full supply chain evaluation with our suppliers and have implemented a number of measures to strengthen processes, for which we are already seeing significant improvements.
“Despite the impact of these issues I am confident that, following the improvements made, we are entering 2018 in a much stronger position."
In the last few months of 2017 orders have increased and the group expects further new distributors to be appointed in the new year.
Following a recent £2mln fundraise, the company also has sufficient cash to meet its working capital requirements through 2018.